Achieving Nutritional Adequacy Of Vitamins E and K With An Egg/Plant-Based Food Pairing - Study 1

Sponsor
Ohio State University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04287816
Collaborator
(none)
10
1
6
18
0.6

Study Details

Study Description

Brief Summary

Malnutrition of the fat-soluble nutrients vitamin E (α-tocopherol; αT) and vitamin K (phylloquinone; PQ) is problematic. Since αT and PQ are rich in plant foods (e.g. spinach) that are mostly absent of accessible lipid, dietary patterns that can potentiate αT and PQ bioavailability by pairing vegetables with lipid-rich foods have been emphasized. The purpose of this study is to use deuterium-labeled spinach (containing stable isotopes of αT and PQ) to validate eggs as a dietary tool to improve αT and PQ bioavailability directly from a model plant food, and hence achieve nutrient adequacy. It is expected that compared with deuterium-labeled spinach alone, co-ingestion of eggs will dose- and time-dependently increase plasma bioavailability of spinach-derived deuterium-labeled αT and PQ without affecting time to maximal concentrations or half-lives. The outcome will therefore support an egg-based food pairing that can enhance the health benefits of plant-centric dietary patterns.

Condition or Disease Intervention/Treatment Phase
  • Other: Zero hard-boiled egg at 0 h
  • Other: One hard-boiled egg at 0 h
  • Other: Two hard-boiled eggs at 0 h
  • Other: Three hard-boiled eggs at 0 h
  • Other: One hard-boiled egg at 3 h
  • Other: One hard-boiled egg at 0 h + One hard-boiled egg at 3 h
N/A

Detailed Description

In the US, 92-96% and 43-63% of men and women do not meet recommended intakes for αT and PQ, respectively. Dietary recommendations strongly encourage a diet rich in fruits and vegetables to meet dietary αT and PQ requirements. However, αT and PQ bioavailability from most plant foods is quite poor, thereby emphasizing a need for effective food pairings that can enhance the absorption and promote adequate status of these health-promoting nutrients. The objective of this application is to use deuterium-labeled spinach (containing stable isotopes of αT and PQ) to validate eggs as a dietary tool to improve αT and PQ bioavailability directly from a model plant food, and hence achieve nutrient adequacy. Our hypothesis is that the bioavailability of αT and PQ from deuterium-labeled spinach will be potentiated by egg intake in a dose-dependent manner by increasing their secretion in intestinal-derived chylomicrons.

To test this, our specific aim is to assess egg-mediated improvements in αT and PQ bioavailability by conducting a randomized cross-over pharmacokinetic study in healthy men and women. In Study Arms 1-4, participants will ingest deuterium-labeled spinach (containing 2 mg αT and 500 μg PQ) with 0, 1, 2, or 3 hardboiled eggs (containing 0, 4.8, 9.6, or 14.4 g total fat, respectively). In Study Arm 5, participants will ingest spinach alone followed by 1 egg 3-hours later. In Study Arm 6, participants will ingest spinach with 1 egg followed by another egg 3-hours later. Thus, Study Arms 1-4 will test the dose-dependent effects of eggs on nutrient bioavailability and Study Arms 5-6 (with comparison to Study Arms 1 and 2) will test the 'timing'-dependent effects of eggs on nutrient bioavailability. Eucaloric diets will be controlled for αT and PQ intakes for 3 d prior to and during the initial 24 h of each trial to minimize heterogeneity of pharmacokinetic responses. Spinach-derived deuterium-labeled αT and PQ will be measured in plasma and isolated chylomicrons collected at timed intervals from 0-72 h post-meal ingestion, and biomarkers of antioxidant status and oxidative distress will be assessed at baseline (0 h) of each trial. Outcomes from this study are expected to demonstrate a dose- and time-dependent function of eggs to increase deuterium-labeled αT and PQ bioavailability (based on AUC0-72 h, Cmax, and % estimated absorption).

The rationale for this study is that, by establishing the efficacy of eggs to potentiate plant-derived fat-soluble nutrient bioavailability, a strong framework will exist for an easily implementable health-promoting food pairing strategy to overcome malnutrition of αT and PQ.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
10 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Achieving Nutritional Adequacy Of Vitamins E and K With An Egg/Plant-Based Food Pairing - Study 1
Actual Study Start Date :
Jun 1, 2021
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Zero hard-boiled egg at 0 h

No eggs will be consumed on the test day. Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone prior to the 72-h pharmacokinetics trial.

Other: Zero hard-boiled egg at 0 h
No eggs will be consumed on test day along with spinach consumption

Experimental: One hard-boiled egg at 0 h

Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 1 hard-boiled egg prior to the 72-h pharmacokinetics trial.

Other: One hard-boiled egg at 0 h
One egg will be consumed on test day along with spinach consumption

Experimental: Two hard-boiled eggs at 0 h

Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 2 hard-boiled eggs prior to the 72-h pharmacokinetics trial.

Other: Two hard-boiled eggs at 0 h
Two eggs will be consumed on test day along with spinach consumption

Experimental: Three hard-boiled eggs at 0 h

Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 3 hard-boiled eggs prior to the 72-h pharmacokinetics trial.

Other: Three hard-boiled eggs at 0 h
Three eggs will be consumed on test day along with spinach consumption

Experimental: One hard-boiled egg at 3 h

Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone at 0 h prior to the 72-h pharmacokinetics trial followed by 1 hard-boiled egg 3 hours after spinach consumption.

Other: One hard-boiled egg at 3 h
One egg will be consumed on test day three hours after spinach consumption

Experimental: One hard-boiled egg at 0 h + One hard-boiled egg at 3 h

Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 1 hard-boiled egg at 0 h prior to the 72-h pharmacokinetics trial followed by 1 egg 3 hours after spinach consumption.

Other: One hard-boiled egg at 0 h + One hard-boiled egg at 3 h
Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption

Outcome Measures

Primary Outcome Measures

  1. Vitamin E Bioavailability [0, 3, 4.5, 6, 7.5, 9, 12, 24, 36, 48, 72 hours post-ingestion of spinach]

    Area under the curve of deuterium-labeled alpha-tocopherol

  2. Vitamin E Cmax [0-72 hours post-ingestion of spinach]

    Maximum plasma concentration of deuterium-labeled alpha-tocopherol

  3. Estimated Absorption (%Dose) of Vitamin E [0-72 hours post-ingestion of spinach]

    Absorption of deuterium-labeled alpha-tocopherol

  4. Vitamin K Bioavailability [0, 3, 4.5, 6, 7.5, 9, 12, 24, 36, 48, 72 hours post-ingestion of spinach]

    Area under the curve of deuterium-labeled phylloquinone

  5. Vitamin K Cmax [0-72 hours post-ingestion of spinach]

    Maximum plasma concentration of deuterium-labeled phylloquinone

  6. Estimated Absorption (%Dose) of Vitamin K [0-72 hours post-ingestion of spinach]

    Absorption of deuterium-labeled phylloquinone

Secondary Outcome Measures

  1. Vitamin E Tmax [0-72 hours post-ingestion of spinach]

    Time to reach maximum plasma concentration of deuterium-labeled alpha-tocopherol

  2. Chylomicron Vitamin E [0, 3, 4.5, 6, 7.5, 9, 12 hours post-ingestion of spinach]

    Deuterium-labeled alpha-tocopherol concentration in chylomicron

  3. Elimination Rate of Vitamin E [0-72 hours post-ingestion of spinach]

    Rate of plasma elimination of deuterium-labeled alpha-tocopherol

  4. Vitamin K Tmax [0-72 hours post-ingestion of spinach]

    Time to reach maximum plasma concentration of deuterium-labeled phylloquinone

  5. Chylomicron Vitamin K [0, 3, 4.5, 6, 7.5, 9, 12 hours post-ingestion of spinach]

    Deuterium-labeled phylloquinone concentration in chylomicron

  6. Elimination Rate of Vitamin K [0-72 hours post-ingestion of spinach]

    Rate of plasma elimination of deuterium-labeled phylloquinone

Other Outcome Measures

  1. Vitamin C [Prior to (0 hour) spinach consumption]

    Baseline plasma vitamin C concentration

  2. Malondialdehyde [Prior to (0 hour) spinach consumption]

    Baseline plasma malondialdehyde concentration

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Body Mass Index (BMI) = 19-25 kg/m2

  • Normolipidemic (total cholesterol <240 mg/dL; triglyceride <150 mg/dL)

  • Fasting glucose <100 mg/dL

  • Normal hematocrit level (41%-50% for men and 36%-48% for women)

  • Normal hemoglobin level (13.5-17.5 g/dL for men and 12.0-15.5 g/dL for women)

  • No use of dietary supplements for >1 month

  • No use of medications that affect lipid or glucose metabolism

  • Non-smoker

  • No history of gastrointestinal disorders

Exclusion Criteria:
  • Egg allergy

  • Alcohol intake > 2 drinks per day

  • Aerobic activity >7 h/wk

  • Body mass change >2 kg in the past 1 month

  • Women who are pregnant, lactating, or initiated or changed birth control in the past 3 month

  • Vegetarian

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ohio State University Columbus Ohio United States 43210

Sponsors and Collaborators

  • Ohio State University

Investigators

  • Principal Investigator: Richard S Bruno, Ph.D., Ohio State University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Richard Bruno, Professor and Principal Investigator, Ohio State University
ClinicalTrials.gov Identifier:
NCT04287816
Other Study ID Numbers:
  • 2019H0504-A
First Posted:
Feb 27, 2020
Last Update Posted:
Dec 20, 2021
Last Verified:
Dec 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Richard Bruno, Professor and Principal Investigator, Ohio State University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 20, 2021